Cartesian Therapeutics
RNAC
38 hedge funds and large institutions have $95M invested in Cartesian Therapeutics in 2019 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 9 closing their positions.
193% more capital invested
Capital invested by funds: $32.4M → $95M (+$62.6M)
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
6% more funds holding
Funds holding: 36 → 38 (+2)
1.41% more ownership
Funds ownership: 1.37% → 2.78% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$8.45M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$7.39M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$5.28M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$5.28M |
| 5 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$3.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
-$4.46M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$942K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$255K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$166K |
| 5 |
PCM
Proxima Capital Management
New York
|
-$53K |
RNAC Hedge Fund Activity: Q4 2019 in Review
38 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q4 2019, worth a combined $95M — up 193% from $32.4M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new RNAC positions and 9 closed out — a net gain of 2 holders — while 10 added to existing stakes and 11 trimmed.
The largest buyer was Mangrove Partners, opening a new position worth an estimated $8.45M. The largest seller was Man Group, cutting an estimated $4.46M.
- 38 institutional investors held Cartesian Therapeutics (RNAC) as of Q4 2019, up from 36 in Q3 2019.
- Funds reported $95M of Cartesian Therapeutics stock for Q4 2019, up 193% quarter-over-quarter.
- 11 funds opened new Cartesian Therapeutics positions in Q4 2019 and 9 closed out, a net change of +2 holders.
- The largest Cartesian Therapeutics buyer in Q4 2019 was Mangrove Partners, an estimated $8.45M added.
- The largest Cartesian Therapeutics seller in Q4 2019 was Man Group, an estimated $4.46M sold.
Based on aggregated 13F filings for Q4 2019.